LGL Partners LLC Cuts Stock Position in Novo Nordisk A/S (NYSE:NVO)

LGL Partners LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 17.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,773 shares of the company’s stock after selling 782 shares during the quarter. LGL Partners LLC’s holdings in Novo Nordisk A/S were worth $325,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of NVO. Autumn Glory Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 39.9% during the 3rd quarter. Autumn Glory Partners LLC now owns 22,671 shares of the company’s stock valued at $2,699,000 after purchasing an additional 6,463 shares during the last quarter. Old Port Advisors increased its position in Novo Nordisk A/S by 4.8% during the 3rd quarter. Old Port Advisors now owns 5,094 shares of the company’s stock valued at $607,000 after buying an additional 233 shares in the last quarter. Traynor Capital Management Inc. raised its stake in Novo Nordisk A/S by 3.4% in the third quarter. Traynor Capital Management Inc. now owns 305,404 shares of the company’s stock valued at $36,364,000 after buying an additional 10,019 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in Novo Nordisk A/S by 5.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 21,000 shares of the company’s stock worth $2,500,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Fidelis Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 107.0% during the third quarter. Fidelis Capital Partners LLC now owns 20,313 shares of the company’s stock worth $2,351,000 after acquiring an additional 10,500 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 0.4 %

Shares of Novo Nordisk A/S stock opened at $90.94 on Wednesday. Novo Nordisk A/S has a 1 year low of $77.82 and a 1 year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market cap of $408.07 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 0.90 and a beta of 0.45. The firm has a fifty day moving average price of $85.32 and a 200 day moving average price of $107.42.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 47.72%.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on NVO shares. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an “equal weight” rating for the company. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.